NCT02626364 2020-07-20
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Arog Pharmaceuticals, Inc.
Phase 2 Completed
Clinical Trials
3 trialsNCT01229644 2018-07-05
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Arog Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn